Floatz logo

Infliximab

Cachexia

Centocor, Inc.monoclonal_antibodyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cachexia cohort.

Asset / SponsorPhaseRating
Anamorelin
Helsinn Therapeutics (U.S.), Inc
Phase 3BB
Ponsegromab
Pfizer
Phase 2/3BB
MEGESTROL ACETATE IMPURITY B
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3BB
Nanocrystalline Megestrol Acetate Suspension
Nanfang Hospital, Southern Medical University
Phase 3BB
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Mayo Clinic
Phase 3B

View all 29 →

Same molecule, other indications

Infliximab is also rated in:

hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →
Crohn diseaseDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →